It has been reported that IL-5 levels in serum can be used as a biomarker for the blood eosinophilia asthma phenotype and that targeting IL-5 or its receptor alpha subunit (IL-5Ra) reduces eosinophil numbers and disease severity [20-21]. This evidence concerns the gene IL5 and asthma.